BioNTech has resolved a longstanding patent dispute with CureVac and GSK through a $740 million settlement plus royalty payments. This agreement clears a significant hurdle for BioNTech's ongoing $1.25 billion acquisition of CureVac, consolidating mRNA vaccine intellectual property rights amid growing commercial interest. The settlement illustrates the complex patent landscape surrounding mRNA technology, which underpinned COVID-19 vaccines’ rapid development and commercialization.